United Kingdom

People: Alkermes Plc (ALKS.OQ)

ALKS.OQ on NASDAQ Stock Exchange Global Select Market

18 Sep 2019
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Pops, Richard 

Mr. Richard F. Pops is Chairman of the Board, Chief Executive Officer of the Company. Prior to assuming his current positions, Mr. Pops served as Chief Executive Officer of Alkermes, Inc. from February 1991 to April 2007 and as Chief Executive Officer and President from September 2009 until September 2011. Mr. Pops serves on the board of directors of Neurocrine Biosciences, Inc., Acceleron Pharma, Inc. and Epizyme Inc., all of which are publicly traded biotechnology companies. Mr. Pops also serves on the board of directors of the Biotechnology Innovation Organization (“BIO”), PhRMA and the National Health Council. He has previously served on the board of directors of two other publicly traded biopharmaceutical companies, Sirtris Pharmaceuticals from 2004 to 2008, and CombinatoRx, Incorporated from 2001 to 2009. Mr. Pops also served on the board of directors of Reliant Pharmaceuticals, a privately held pharmaceutical company purchased by GlaxoSmithKline in 2007, and on the advisory board of Polaris Venture Partners. He was a member of the Harvard Medical School Board of Fellows through June 2012. Mr. Pops is also on the advisory board for the Addiction Policy Forum.

Basic Compensation

Total Annual Compensation, USD 964,204
Restricted Stock Award, USD 1,909,950
Long-Term Incentive Plans, USD --
All Other, USD 6,506,340
Fiscal Year Total, USD 9,380,490

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 150,000 5,919,130.00
Name Fiscal Year Total

Richard Pops


James Frates


Elliot Ehrich


Iain Brown


David Gaffin


Michael Landine

As Of  31 Dec 2017